Strike three: Allergan slides on potential Restasis generics
This article was originally published in Scrip
Executive Summary
Allergan came out swinging at the beginning of 2013, but the Irvine, California-based company faced its third strike of the year when the US FDA issued guidance for generic drug makers developing reduced-priced competition for the dry eye drug Restasis (cyclosporine).
You may also be interested in...
Surprise! Viatris Proves Its Worth With First Generic Restasis Approval
In one of the most keenly-watched markets, Viatris has emerged as the winner of approval for the first US generic version of AbbVie’s Restasis 0.05% ophthalmic emulsion, years after its IP was taken down. Numerous firms and analysts had acknowledged the complexity of the reference brand.
Pharma Q3 Results Preview: Pfizer, Allergan, Sanofi, Teva & AstraZeneca
Pfizer’s CEO will likely shed more light on the company’s on-off-on attitude towards its consumer health business, while Allergan will certainly have a lot of explaining to do regarding its Restasis patent protection strategy. Sanofi, Teva and AstraZeneca are also scheduled to report Q3 results in the coming days. Scrip outlines the key issues to watch for.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.